[HEPDART 2017] 控制HBsAg作为影响HBV治愈的组合策略的关键组成部

StephenW

[HEPDART 2017]
Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure
Dr. M. Sofia, Arbutus Biopharma, USA

In chronically infected HBV patients, HBsAg is believed to play a significant role in control of the host immune response
HBV functional cures are associated with the loss of HBsAg
siRNA / LNP modalities have been shown to reduce HBsAg
levels in the clinic
Novel small molecule RNA destabilizers show potential to significantly reduce levels of HBsAg in addition to reduction of HBV DNA and other viral antigens
Combinations of either an siRNA/LNP or RNA destabilizer agent with other MOA agents have shown additive or synergistic anti-HBV effects in preclinical models.

StephenW notes:
Recommended.
siRNA/LNP - ARB-1467 and ARB-1740
RNA destabilizer agent -  AB-452

[HEPDART 2017]
控制HBsAg作为影响HBV治愈的组合策略的关键组成部分
M. Sofia博士，美国Arbutus生物制药公司

在慢性感染的HBV患者中，HBsAg被认为在控制宿主免疫反应方面发挥重要作用
HBV功能治疗与HBsAg的丢失有关
siRNA/ LNP模式已被证明可以降低HBsAg
在诊所的水平
小分子RNA去稳定剂除了减少HBV DNA和其他病毒抗原外，还显示出显着降低HBsAg水平的潜力
siRNA / LNP或RNA去稳定剂与其他MOA药剂的组合在临床前模型中显示出相加或协同的抗HBV作用。

StephenW指出：
推荐的。
siRNA / LNP-ARB-1467和ARB-1740
RNA去稳定剂 -  AB-452

幻灯片：http://regist2.virology-education.com/presentations/2017/HEPDART/42_Sofia.pdf

newchinabok

sw老师，有核衣壳抑制剂的信息么?

StephenW

回复 newchinabok 的帖子

没有具体的信息. HepDart是一个高级别的肝炎会议.

antiHBVren

乙肝基金组织倒是没有什么更新
http://www.hepb.org/treatment-and-management/drug-watch/